Navigation Links
Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Date:8/19/2007

KING OF PRUSSIA, Pa., Aug. 2 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) today revealed that recent experiments with its small-molecule MIF inhibitors showed oral efficacy in animal models. Based on these results, the Company announced that it is advancing one of these compounds into preclinical development.

Macrophage Migration Inhibitory Factor, or MIF, is linked to many conditions, including arthritis, asthma, cancer, sepsis, inflammatory bowel disease and various infections and autoimmune disorders. Neutralization of MIF biological activity has been shown to have a protective effect against these diseases. CPSI has an extensive patent portfolio focused on MIF, covering various methods for neutralization, including small molecules. These compounds were recently shown to be effective in animal models of multiple sclerosis (MS) and arthritis when administered orally.

The MS animal experiments were conducted in the laboratories of Dr. Abhay Satoskar and Dr. Caroline C. Whitacre, both of Ohio State University in Columbus, OH. Dr. Satoskar stated: "The therapeutic efficacy of these compounds was impressive with no outward signs of toxicity. These findings indicate that small-molecule MIF inhibitors are viable drug candidates for treating other autoimmune and inflammatory diseases in which MIF has been identified as a pathogenic factor." Dr. Whitacre adds: "The inhibitors were especially effective in treating disease that had already started, which is traditionally the most difficult hurdle for a new therapy. We are very encouraged by these results."

The arthritis experiments were conducted under the guidance of Drs. Thais M. Sielecki and Vidal F. de la Cruz of Cytokine PharmaSciences, Inc. Dr. Sielecki observed: "We are encouraged to have a small molecule MIF inhibitor that is orally active. MIF is an important target in many diseases and an oral treatment is a definite advantage." Dr. Sielecki will present the MS and arthritis result
'/>"/>

SOURCE Cytokine PharmaSciences, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
3. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
9. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) has announced ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" ... been the topic of fascination since the era of the ... and the Soviet Russia. Earlier even a small glimpse of ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... Mass., Aug. 12, 2011 PLC Systems Inc. (OTCBB: ... today reported financial results for the three- and six ... include the company,s RenalGuard® operations, since PLC completed the ... Corp. during the first quarter of 2011. Results from ...
... Midwest Business Group on Health in collaboration ... speakers and agenda for the fifth annual Pharmacy ... at the InterContinental Chicago O,Hare. The program provides human ... other health care stakeholders, with the information and tools ...
Cached Medicine Technology:PLC Systems Reports Second Quarter 2011 Results 2PLC Systems Reports Second Quarter 2011 Results 3PLC Systems Reports Second Quarter 2011 Results 4PLC Systems Reports Second Quarter 2011 Results 5PLC Systems Reports Second Quarter 2011 Results 6Featured Speakers Announced for 5th Annual Pharmacy Benefits Academy, August 24-25 in Chicago 2
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... School of Medicine has received a $10 million gift ... endow and name the Walter S. and Lucienne Driskill ... will support graduate student training in the life sciences ... recruiting superb and highly competitive candidates for the medical ...
... Alan Mozes HealthDay Reporter , TUESDAY, Dec. 13 ... plant for its amphetamine-like effect appears to raise the risk ... a large new study from the Middle East. The ... emigration has increasingly brought khat-chewing to the shores of both ...
... UC Irvine researchers have uncovered an important source ... which is increasingly common due to the epidemic of ... emeritus of medicine and physiology & biophysics, found that ... called the tight junction, that normally seal the space ...
... News) -- A procedure in which doctors use a catheter ... beneficial, a new Norwegian study finds. DVT involves a ... lungs and become even more dangerous. Nearly half of patients ... called post-thrombotic syndrome, characterized by pain, swelling, a sensation of ...
... Harbor, NY -- Something rotten never smelled so sweet. ... Cold Spring Harbor Laboratory (CSHL) are telling one another as they ... They have discovered that hydrogen sulfide (H2S) the flammable, highly ... eggs in landfills and sewers plays an important role in ...
... to different moral standards than other organizations, according to ... Research . "Imagine the CEO of a ... business of maximizing shareholder profitability and fully intends to ... should be very high because of limited competition," write ...
Cached Medicine News:Health News:Northwestern receives $10 million gift for life sciences graduates 2Health News:Chewing Khat Raises Heart Disease, Death Risk: Study 2Health News:Chewing Khat Raises Heart Disease, Death Risk: Study 3Health News:Major cause of chronic kidney disease-related inflammation is identified 2Health News:Procedure May Lower Complications After Leg Clots 2Health News:Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding 2Health News:Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding 3Health News:Commercial or communal: Why is outsourcing taboo for churches and pharmaceutical companies? 2
... articulation maintains full inter-changeability. Modular tibial components ... fit. The Maxim Knee system is ... with expanded options to address surgeon preferences ... for use in total knee replacements both ...
Tibial distractor...
Simple, stable knee positioning triangles for lower extremity surgery. The triangles are radiolucent, autoclavable, and use latex-free, sterile, disposable pads....
... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
Medicine Products: